1. Market Size and Growth Rate:

The global spermidine market was approximately RMB 2.368 billion in 2025, and is expected to reach RMB 4.190 billion by 2032, with a CAGR of 8.6%. The Chinese market is growing faster, with a scale of RMB 1.43 billion in 2024, a year-on-year increase of 23.8%, and its global share continues to rise. Core drivers: aging population, surging demand for anti-aging, declining biosynthesis costs, and increasing food/pharmaceutical compliance requirements.

1. Application Structure: Dietary supplements (accounting for >75%): anti-aging, cell repair, cardiovascular and brain health, gut health, with capsules and powders as mainstream forms. Functional foods: grains, beverages, and probiotic compound products are rapidly gaining traction. Biomedicine: cell culture, neuroprotection, metabolic disease drug development, clinical nutrition. Agriculture: plant stress resistance agents, growth regulators, seed treatments.

1. Compliance Issues: United States: Spermidine is currently not on the Generally Recognized as Safe (GRAS) notification list; selling it as a dietary supplement requires self-responsibility for safety. China: Spermidine has not yet been approved as a food ingredient or nutritional fortifier; applying for new food ingredient status is the main pathway. European Union: Official regulation (EU) 2020/443, the only clear food compliance pathway for spermidine: “wheat germ extract rich in spermidine” has been approved as a Novel Food in the EU.

1. Competitive Landscape: International: Thermo Fisher, Merck, Iris Biotech, Biosynth, focusing on high-purity reagent grade with high prices. Domestic: Biosynthesis companies are rapidly emerging, mainly using fermentation/whole-cell catalysis routes, with significant cost advantages, entering the raw material and end-brand markets. Trends: Raw material production is shifting to biosynthesis, with chemical synthesis gradually exiting the food/pharmaceutical fields; end products are upgrading to compound formulas (spermidine + NAD+, PQQ, ergothioneine).

1. Core Logic for Product Selection: High barriers: Clear autophagy anti-aging mechanism, solid clinical evidence, distinct from ordinary nutrients. High growth: Dual tracks of anti-aging and chronic disease prevention, rigid demand, low penetration rate. Industrializable: Mature biosynthesis technology, continuously decreasing costs, strong certainty of large-scale profitability. Compliance-friendly: Natural equivalent, applicable in food/feed/pharmaceutical scenarios.

1. Summary and Outlook: Spermidine is a high-quality target for biosynthesis product selection: clear natural function, mature synthesis pathway, rapid market growth, and green manufacturing aligned with policy direction. Technology: SAM pathway whole-cell catalysis has reached industrial level, with 17.83 g/L as the current benchmark; continuous optimization can further reduce costs and increase efficiency. Market: Extending from raw materials to functional foods, dietary supplements, and pharmaceutical intermediates, with the value chain continuously moving upward. Future: With the clinical translation of autophagy mechanisms and the decline in biomanufacturing costs, spermidine is expected to become a core blockbuster product in anti-aging and health raw materials.

generalsteel.cheng

See Full Bio